Despite red flag from FDA, controversial ALS cell therapy developer says it may still march ahead anyway
When BrainStorm Cell Therapeutics broke out the abysmal numbers in its Phase III trial, the biotech insisted that the FDA was eager to review …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
